Infinity Pharmaceuticals, Inc. (INFI) Short Interest Up 178.0% in October

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 2,070,777 shares, a growth of 178.0% from the October 13th total of 744,999 shares. Based on an average daily volume of 1,834,208 shares, the short-interest ratio is presently 1.1 days. Approximately 4.3% of the company’s shares are short sold.

Infinity Pharmaceuticals (NASDAQ INFI) opened at $1.89 on Thursday. Infinity Pharmaceuticals has a 52-week low of $0.93 and a 52-week high of $3.84.

Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.06. The company had revenue of $6.00 million for the quarter, compared to analyst estimates of $14.70 million. During the same period in the prior year, the firm posted ($0.39) earnings per share. analysts predict that Infinity Pharmaceuticals will post -0.94 EPS for the current year.

In other Infinity Pharmaceuticals news, insider Value Fund L. P. Biotechnology purchased 1,600,046 shares of the business’s stock in a transaction on Wednesday, October 4th. The shares were bought at an average cost of $1.26 per share, for a total transaction of $2,016,057.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 6.81% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Infinity Pharmaceuticals by 27.7% in the first quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock valued at $15,187,000 after purchasing an additional 1,021,128 shares in the last quarter. Platinum Investment Management Ltd. boosted its holdings in Infinity Pharmaceuticals by 74.3% in the third quarter. Platinum Investment Management Ltd. now owns 1,411,832 shares of the biotechnology company’s stock valued at $1,877,000 after purchasing an additional 601,600 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Infinity Pharmaceuticals by 32.7% in the second quarter. Dimensional Fund Advisors LP now owns 652,481 shares of the biotechnology company’s stock valued at $1,024,000 after purchasing an additional 160,814 shares in the last quarter. Legal & General Group Plc boosted its holdings in Infinity Pharmaceuticals by 2,430.0% in the second quarter. Legal & General Group Plc now owns 349,346 shares of the biotechnology company’s stock valued at $548,000 after purchasing an additional 335,538 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Infinity Pharmaceuticals by 4.5% in the first quarter. Geode Capital Management LLC now owns 345,366 shares of the biotechnology company’s stock valued at $1,114,000 after purchasing an additional 15,005 shares in the last quarter. 67.02% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts have recently commented on the company. ValuEngine raised Infinity Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 12th. Wells Fargo & Company raised Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Thursday, October 12th. Finally, Zacks Investment Research raised Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th.

ILLEGAL ACTIVITY NOTICE: “Infinity Pharmaceuticals, Inc. (INFI) Short Interest Up 178.0% in October” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.themarketsdaily.com/2017/11/16/infinity-pharmaceuticals-inc-infi-short-interest-up-178-0-in-october.html.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply